Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Volume: 19, Issue: 12, Pages: 1654 - 1667
Published: Dec 1, 2018
Abstract
Summary null Background null Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung cancer, most of whom had CNS metastases and progression after ALK-directed therapy. We aimed to analyse the overall and intracranial antitumour activity of lorlatinib in patients with...
Paper Details
Title
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Published Date
Dec 1, 2018
Volume
19
Issue
12
Pages
1654 - 1667
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.